{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:02:51Z","timestamp":1791385371159,"version":"4.3.3"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11914-020-00587-2","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T08:03:17Z","timestamp":1589184197000},"page":"312-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Delivery of RNAi-Based Therapeutics for Bone Regeneration"],"prefix":"10.1007","volume":"18","author":[{"given":"Dominic W.","family":"Malcolm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde","family":"Overby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle S. W.","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"587_CR1","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"JK Lam","year":"2015","unstructured":"Lam JK, et al. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"587_CR2","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.biomaterials.2011.12.021","volume":"33","author":"WWY Yau","year":"2012","unstructured":"Yau WWY, et al. Directing stem cell fate by controlled RNA interference. Biomaterials. 2012;33(9):2608\u201328.","journal-title":"Biomaterials"},{"issue":"1","key":"587_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"\u2022 Adams D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321 This paper details results from the Phase 3 clinical trial of Patisiran that resulted in the first FDA approved siRNA therapy to treat hereditary transthyretin amyloidosis.","journal-title":"N Engl J Med"},{"key":"587_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.copbio.2016.02.029","volume":"40","author":"MR Newman","year":"2016","unstructured":"Newman MR, Benoit DS. Local and targeted drug delivery for bone regeneration. Curr Opin Biotechnol. 2016;40:125\u201332.","journal-title":"Curr Opin Biotechnol"},{"key":"587_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejpb.2018.02.023","volume":"127","author":"Y Wang","year":"2018","unstructured":"Wang Y, Newman MR, Benoit DSW. Development of controlled drug delivery systems for bone fracture-targeted therapeutic delivery: a review. Eur J Pharm Biopharm. 2018;127:223\u201336.","journal-title":"Eur J Pharm Biopharm"},{"key":"587_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jconrel.2015.09.066","volume":"218","author":"SM Sarett","year":"2015","unstructured":"Sarett SM, Nelson CE, Duvall CL. Technologies for controlled, local delivery of siRNA. J Control Release. 2015;218:94\u2013113.","journal-title":"J Control Release"},{"issue":"7","key":"587_CR7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/jbmr.2860","volume":"31","author":"S Ghadakzadeh","year":"2016","unstructured":"Ghadakzadeh S, Mekhail M, Aoude A, Tabrizian M, Hamdy RC. Small players ruling the hard game: siRNA in bone regeneration. J Bone Miner Res. 2016;31(7):1481.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"587_CR8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7555\/JBR.30.20150110","volume":"30","author":"X Liu","year":"2016","unstructured":"Liu X. Bone site-specific delivery of siRNA. J Biomed Res. 2016;30(4):264\u201371.","journal-title":"J Biomed Res"},{"key":"587_CR9","volume-title":"Musculoskeletal conditions in the United States","author":"A Praemer","year":"1999","unstructured":"Praemer A, Furner S, Rice DP. Musculoskeletal conditions in the United States. Rosemont: American Academy of Orthopaedic Surgeons; 1999."},{"key":"587_CR10","doi-asserted-by":"crossref","unstructured":"Stewart, S., et al., Translational regenerative medicine. Bone regeneration, ed. A. Atala and J.G. Alllickson. Vol. 1.2015: Elsevier606.","DOI":"10.1016\/B978-0-12-410396-2.00024-4"},{"key":"587_CR11","first-page":"97","volume-title":"United States bone and joint decade: the burden of musculoskeletal diseases in the United States","author":"GBJ Andersson","year":"2008","unstructured":"Andersson GBJ, et al. United States bone and joint decade: the burden of musculoskeletal diseases in the United States. Rosemont: American Academy of Orthopaedic Surgeons; 2008. p. 97\u2013161."},{"issue":"2","key":"587_CR12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jcb.22418","volume":"109","author":"DE Komatsu","year":"2010","unstructured":"Komatsu DE, Warden SJ. The control of fracture healing and its therapeutic targeting: improving upon nature. J Cell Biochem. 2010;109(2):302\u201311.","journal-title":"J Cell Biochem"},{"issue":"6","key":"587_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.injury.2011.03.031","volume":"42","author":"R Marsell","year":"2011","unstructured":"Marsell R, Einhorn TA. The biology of fracture healing. Injury. 2011;42(6):551\u20135.","journal-title":"Injury"},{"issue":"5","key":"587_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.semcdb.2008.07.004","volume":"19","author":"A Schindeler","year":"2008","unstructured":"Schindeler A, McDonald M, Bokko P, Little DG. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol. 2008;19(5):459\u201366.","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"587_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2012.1","volume":"8","author":"L Claes","year":"2012","unstructured":"Claes L, Recknagel S, Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat Rev Rheumatol. 2012;8(3):133\u201343.","journal-title":"Nat Rev Rheumatol"},{"key":"587_CR16","unstructured":"Ratko TA, et al. Bone morphogenetic protein: the state of the evidence of on-label and off-label use. Rockville (MD); 2010."},{"issue":"11","key":"587_CR17","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1007\/s11999-011-1865-3","volume":"469","author":"P Kolar","year":"2011","unstructured":"Kolar P, et al. Human early fracture hematoma is characterized by inflammation and hypoxia. Clin Orthop Relat Res. 2011;469(11):3118\u201326.","journal-title":"Clin Orthop Relat Res"},{"key":"587_CR18","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.2741\/3882","volume":"16","author":"TA Franz-Odendaal","year":"2011","unstructured":"Franz-Odendaal TA. Induction and patterning of intramembranous bone. Front Biosci (Landmark Ed). 2011;16:2734\u201346.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"8","key":"587_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/dvdy.23992","volume":"242","author":"CJ Percival","year":"2013","unstructured":"Percival CJ, Richtsmeier JT. Angiogenesis and intramembranous osteogenesis. Dev Dyn. 2013;242(8):909\u201322.","journal-title":"Dev Dyn"},{"issue":"5","key":"587_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM196901302800507","volume":"280","author":"WH Harris","year":"1969","unstructured":"Harris WH, Heaney RP. Skeletal renewal and metabolic bone disease. N Engl J Med. 1969;280(5):253\u20139 contd.","journal-title":"N Engl J Med"},{"issue":"1","key":"587_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00223-013-9790-y","volume":"94","author":"MB Schaffler","year":"2014","unstructured":"Schaffler MB, Cheung WY, Majeska R, Kennedy O. Osteocytes: master orchestrators of bone. Calcif Tissue Int. 2014;94(1):5\u201324.","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"587_CR22","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1073\/pnas.78.5.3204","volume":"78","author":"GA Howard","year":"1981","unstructured":"Howard GA, Bottemiller BL, Turner RT, Rader JI, Baylink DJ. Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism. Proc Natl Acad Sci U S A. 1981;78(5):3204\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"587_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF02409454","volume":"33","author":"GA Rodan","year":"1981","unstructured":"Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption--a hypothesis. Calcif Tissue Int. 1981;33(4):349\u201351.","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"587_CR24","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1073\/pnas.84.7.2024","volume":"84","author":"J Pfeilschifter","year":"1987","unstructured":"Pfeilschifter J, Mundy GR. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A. 1987;84(7):2024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"587_CR25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0006-291X(89)92795-2","volume":"158","author":"RO Oreffo","year":"1989","unstructured":"Oreffo RO, Mundy GR, Seyedin SM, Bonewald LF. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun. 1989;158(3):817\u201323.","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"587_CR26","doi-asserted-by":"publisher","first-page":"21352","DOI":"10.1074\/jbc.M111663200","volume":"277","author":"SL Dallas","year":"2002","unstructured":"Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem. 2002;277(24):21352\u201360.","journal-title":"J Biol Chem"},{"issue":"7","key":"587_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nm.1979","volume":"15","author":"Y Tang","year":"2009","unstructured":"Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15(7):757\u201365.","journal-title":"Nat Med"},{"key":"587_CR28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00003086-198005000-00045","volume":"148","author":"H Hanamura","year":"1980","unstructured":"Hanamura H, et al. Solubilized bone morphogenetic protein (BMP) from mouse osteosarcoma and rat demineralized bone matrix. Clin Orthop Relat Res. 1980;148:281\u201390.","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"587_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jcb.10309","volume":"87","author":"J Fiedler","year":"2002","unstructured":"Fiedler J, R\u00f6derer G, G\u00fcnther KP, Brenner RE. BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem. 2002;87(3):305\u201312.","journal-title":"J Cell Biochem"},{"issue":"9","key":"587_CR30","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1210\/jc.2002-020656","volume":"87","author":"J Rubin","year":"2002","unstructured":"Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab. 2002;87(9):4273\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2 Suppl","key":"587_CR31","doi-asserted-by":"publisher","first-page":"93S","DOI":"10.1016\/8756-3282(95)00186-H","volume":"17","author":"JM Hayden","year":"1995","unstructured":"Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone. 1995;17(2 Suppl):93S\u20138S.","journal-title":"Bone"},{"issue":"Suppl 1","key":"587_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000184833","volume":"45","author":"S Mohan","year":"1996","unstructured":"Mohan S, Baylink DJ. Insulin-like growth factor system components and the coupling of bone formation to resorption. Horm Res. 1996;45(Suppl 1):59\u201362.","journal-title":"Horm Res"},{"issue":"2","key":"587_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jor.23460","volume":"35","author":"P Kostenuik","year":"2017","unstructured":"Kostenuik P, Mirza FM. Fracture healing physiology and the quest for therapies for delayed healing and nonunion. J Orthop Res. 2017;35(2):213\u201323.","journal-title":"J Orthop Res"},{"issue":"7","key":"587_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2460\/javma.231.7.1039","volume":"231","author":"CA Kirker-Head","year":"2007","unstructured":"Kirker-Head CA, Boudrieau RJ, Kraus KH. Use of bone morphogenetic proteins for augmentation of bone regeneration. J Am Vet Med Assoc. 2007;231(7):1039\u201355.","journal-title":"J Am Vet Med Assoc"},{"issue":"3","key":"587_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.bone.2007.04.193","volume":"41","author":"N Rozen","year":"2007","unstructured":"Rozen N, Lewinson D, Bick T, Jacob ZC, Stein H, Soudry M. Fracture repair: modulation of fracture-callus and mechanical properties by sequential application of IL-6 following PTH 1-34 or PTH 28-48. Bone. 2007;41(3):437\u201345.","journal-title":"Bone"},{"issue":"4","key":"587_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nrendo.2011.234","volume":"8","author":"JB Lian","year":"2012","unstructured":"Lian JB, Stein GS, van Wijnen A, Stein JL, Hassan MQ, Gaur T, et al. MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol. 2012;8(4):212\u201327.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"587_CR37","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/jbmr.377","volume":"26","author":"J Zhang","year":"2011","unstructured":"Zhang J, et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J Bone Miner Res. 2011;26(8):1953\u201363.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"587_CR38","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/jcb.22364","volume":"108","author":"I Darwech","year":"2009","unstructured":"Darwech I, Otero J, Alhawagri M, Dai S, Abu-Amer Y. Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis. J Cell Biochem. 2009;108(6):1337\u201345.","journal-title":"J Cell Biochem"},{"issue":"5","key":"587_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.joen.2008.01.024","volume":"34","author":"FS Fahid","year":"2008","unstructured":"Fahid FS, et al. Application of small interfering RNA for inhibition of lipopolysaccharide-induced osteoclast formation and cytokine stimulation. J Endod. 2008;34(5):563\u20139.","journal-title":"J Endod"},{"issue":"12","key":"587_CR40","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.cellsig.2008.08.019","volume":"20","author":"NK Lee","year":"2008","unstructured":"Lee NK, et al. RANKL-induced schlafen2 is a positive regulator of osteoclastogenesis. Cell Signal. 2008;20(12):2302\u20138.","journal-title":"Cell Signal"},{"issue":"1\u20132","key":"587_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1089\/ten.tea.2017.0476","volume":"25","author":"D Sezlev Bilecen","year":"2019","unstructured":"\u2022 Sezlev Bilecen D, Uludag H, Hasirci V. Development of PEI-RANK siRNA complex loaded PLGA nanocapsules for the treatment of osteoporosis. Tissue Eng Part A. 2019;25(1\u20132):34\u201343 This report showed immense promise of controlled release of poly(ethylene imine)-siRNA complexes targeting receptor activator of nuclear factor kappa B (RANK) from poly(lactic acid-co-glycolic acid) nanocapsules to treat osteoporosis. Though in vivo studies are pending, longitudinal knockdown suppressed osteoclast differentiation by ~50%.","journal-title":"Tissue Eng Part A"},{"key":"587_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2015.08.031","volume":"217","author":"Z-K Cui","year":"2015","unstructured":"Cui Z-K, Fan J, Kim S, Bezouglaia O, Fartash A, Wu BM, et al. Delivery of siRNA via cationic Sterosomes to enhance osteogenic differentiation of mesenchymal stem cells. J Control Release. 2015;217:42\u201352.","journal-title":"J Control Release"},{"key":"587_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.biomaterials.2017.06.001","volume":"139","author":"Y Wang","year":"2017","unstructured":"\u2022 Wang Y, Malcolm DW, Benoit DSW. Controlled and sustained delivery of siRNA\/NPs from hydrogels expedites bone fracture healing. Biomaterials. 2017;139:127\u201338 This work was the first report of siRNA to improve fracture healing. Specifically, siRNA-NP complexes, which target WW domain-containing E3 ubiquitin protein ligase 1 (Wwp1), via localized, controlled release from hydrogels expedites fracture healing.","journal-title":"Biomaterials"},{"key":"587_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.blo.0000153279.90512.38","volume":"434","author":"SA Lietman","year":"2005","unstructured":"Lietman SA. Reduction in Gsalpha induces osteogenic differentiation in human mesenchymal stem cells. Clin Orthop Relat Res. 2005;434:231\u20138.","journal-title":"Clin Orthop Relat Res"},{"issue":"12","key":"587_CR45","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1172\/JCI39832","volume":"119","author":"H Li","year":"2009","unstructured":"Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, et al. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest. 2009;119(12):3666\u201377.","journal-title":"J Clin Invest"},{"key":"587_CR46","doi-asserted-by":"publisher","first-page":"26925","DOI":"10.1038\/srep26925","volume":"4","author":"Y Zhang","year":"2016","unstructured":"\u2022 Zhang Y, et al. Bone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defects. Sci Rep. 2016;4:26925 Longitudinal semaphorin4d (Sema4d) knockdown was achieved using siRNA-poly(aspartic acid)-stearylated octaarginine complexes controllably released from a poly(L-lactic acid) (PLLA) scaffold in a 3 mm femur defect in osteoporotic rats. Higher bone volume\/total volume bone mineral density and number of osteoblasts were observed in rats treated with scaffolds loaded with siRNA-Sema4d.","journal-title":"Sci Rep"},{"issue":"11","key":"587_CR47","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1177\/0022034514552676","volume":"93","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Wei L, Miron RJ, Zhang Q, Bian Z. Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d. J Dent Res. 2014;93(11):1095\u2013100.","journal-title":"J Dent Res"},{"key":"587_CR48","doi-asserted-by":"crossref","unstructured":"Zhang B, et al. MicroRNA-378 promotes osteogenesis-angiogenesis coupling in BMMSCs for potential bone regeneration. Anal Cell Pathol. 2018;2018.","DOI":"10.1155\/2018\/8402390"},{"issue":"21","key":"587_CR49","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1016\/j.biomaterials.2013.03.052","volume":"34","author":"Y Li","year":"2013","unstructured":"Li Y, Fan L, Liu S, Liu W, Zhang H, Zhou T, et al. The promotion of bone regeneration through positive regulation of angiogenic\u2013osteogenic coupling using microRNA-26a. Biomaterials. 2013;34(21):5048\u201358.","journal-title":"Biomaterials"},{"issue":"7","key":"587_CR50","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1074\/jbc.M509430200","volume":"281","author":"H Kaneki","year":"2006","unstructured":"Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE, et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem. 2006;281(7):4326\u201333.","journal-title":"J Biol Chem"},{"issue":"6","key":"587_CR51","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/jbmr.28","volume":"25","author":"L Zhao","year":"2010","unstructured":"Zhao L, et al. Smurf1 inhibits mesenchymal stem cell proliferation and differentiation into osteoblasts through JunB degradation. J Bone Miner Res. 2010;25(6):1246\u201356.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"587_CR52","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/jbmr.1938","volume":"28","author":"L Shu","year":"2013","unstructured":"Shu L, Zhang H, Boyce BF, Xing L. Ubiquitin E3 ligase Wwp1 negatively regulates osteoblast function by inhibiting osteoblast differentiation and migration. J Bone Miner Res. 2013;28(9):1925\u201335.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"587_CR53","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/stem.703","volume":"29","author":"L Zhao","year":"2011","unstructured":"Zhao L, Huang J, Zhang H, Wang Y, Matesic LE, Takahata M, et al. Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells. 2011;29(10):1601\u201310.","journal-title":"Stem Cells"},{"issue":"8","key":"587_CR54","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/stem.1395","volume":"31","author":"H Zhang","year":"2013","unstructured":"Zhang H, Xing L. Ubiquitin e3 ligase itch negatively regulates osteoblast differentiation from mesenchymal progenitor cells. Stem Cells. 2013;31(8):1574\u201383.","journal-title":"Stem Cells"},{"issue":"5","key":"587_CR55","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1091\/mbc.e08-03-0308","volume":"20","author":"D Bhandari","year":"2009","unstructured":"Bhandari D, Robia SL, Marchese A. The E3 ubiquitin ligase atrophin interacting protein 4 binds directly to the chemokine receptor CXCR4 via a novel WW domain-mediated interaction. Mol Biol Cell. 2009;20(5):1324\u201339.","journal-title":"Mol Biol Cell"},{"issue":"34","key":"587_CR56","doi-asserted-by":"publisher","first-page":"23084","DOI":"10.1074\/jbc.M709848200","volume":"283","author":"R Guo","year":"2008","unstructured":"Guo R, Yamashita M, Zhang Q, Zhou Q, Chen D, Reynolds DG, et al. Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem. 2008;283(34):23084\u201392.","journal-title":"J Biol Chem"},{"issue":"1","key":"587_CR57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cell.2005.01.035","volume":"121","author":"M Yamashita","year":"2005","unstructured":"Yamashita M, Ying SX, Zhang GM, Li C, Cheng SY, Deng CX, et al. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell. 2005;121(1):101\u201313.","journal-title":"Cell"},{"key":"587_CR58","doi-asserted-by":"crossref","unstructured":"Yao Z, et al. NF-kappaB RelB negatively regulates osteoblast differentiation and bone formation. J Bone Miner Res. 2013.","DOI":"10.1002\/jbmr.2108"},{"issue":"24","key":"587_CR59","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1016\/j.biomaterials.2014.04.048","volume":"35","author":"MK Nguyen","year":"2014","unstructured":"Nguyen MK, et al. Sustained localized presentation of RNA interfering molecules from in situ forming hydrogels to guide stem cell osteogenic differentiation. Biomaterials. 2014;35(24):6278\u201386.","journal-title":"Biomaterials"},{"key":"587_CR60","doi-asserted-by":"crossref","unstructured":"Huynh CT, et al. Cytocompatible catalyst-free photodegradable hydrogels for light-mediated RNA release to induce hMSC osteogenesis. ACS Biomater Sci Eng. 2017.","DOI":"10.1021\/acsbiomaterials.6b00796"},{"issue":"3","key":"587_CR61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/jbmr.1798","volume":"28","author":"N Yang","year":"2013","unstructured":"Yang N, Wang G, Hu C, Shi Y, Liao L, Shi S, et al. Tumor necrosis factor alpha suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency-induced osteoporosis. J Bone Miner Res. 2013;28(3):559\u201373.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"587_CR62","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/jcb.24479","volume":"114","author":"Y Mei","year":"2013","unstructured":"Mei Y, Bian C, Li J, du Z, Zhou H, Yang Z, et al. miR-21 modulates the ERK-MAPK signaling pathway by regulating SPRY2 expression during human mesenchymal stem cell differentiation. J Cell Biochem. 2013;114(6):1374\u201384.","journal-title":"J Cell Biochem"},{"issue":"9","key":"587_CR63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrg3978","volume":"16","author":"A Wittrup","year":"2015","unstructured":"Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16(9):543\u201352.","journal-title":"Nat Rev Genet"},{"issue":"26","key":"587_CR64","doi-asserted-by":"publisher","first-page":"7967","DOI":"10.1021\/bi0343774","volume":"42","author":"DA Braasch","year":"2003","unstructured":"Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry. 2003;42(26):7967\u201375.","journal-title":"Biochemistry"},{"issue":"6","key":"587_CR65","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/hep.20702","volume":"41","author":"DV Morrissey","year":"2005","unstructured":"Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005;41(6):1349\u201356.","journal-title":"Hepatology"},{"issue":"11","key":"587_CR66","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.febslet.2010.04.018","volume":"584","author":"S Sorrentino","year":"2010","unstructured":"Sorrentino S. The eight human \"canonical\" ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. FEBS Lett. 2010;584(11):2194\u2013200.","journal-title":"FEBS Lett"},{"issue":"15","key":"587_CR67","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1016\/S0021-9258(18)34185-1","volume":"257","author":"JL Weickmann","year":"1982","unstructured":"Weickmann JL, Glitz DG. Human ribonucleases. Quantitation of pancreatic-like enzymes in serum, urine, and organ preparations. J Biol Chem. 1982;257(15):8705\u201310.","journal-title":"J Biol Chem"},{"issue":"4","key":"587_CR68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/oli.2008.0149","volume":"18","author":"RP Hickerson","year":"2008","unstructured":"Hickerson RP, Vlassov AV, Wang Q, Leake D, Ilves H, Gonzalez-Gonzalez E, et al. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides. 2008;18(4):345\u201354.","journal-title":"Oligonucleotides"},{"issue":"4","key":"587_CR69","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1046\/j.0305-1846.2003.00541.x","volume":"30","author":"J Zamecnik","year":"2004","unstructured":"Zamecnik J, et al. Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol Appl Neurobiol. 2004;30(4):338\u201350.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"12","key":"587_CR70","first-page":"3039","volume":"47","author":"RK Jain","year":"1987","unstructured":"Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039\u201351.","journal-title":"Cancer Res"},{"issue":"Pt 8","key":"587_CR71","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1242\/jcs.066399","volume":"123","author":"M Dominska","year":"2010","unstructured":"Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(Pt 8):1183\u20139.","journal-title":"J Cell Sci"},{"issue":"4","key":"587_CR72","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","volume":"12","author":"J Wang","year":"2010","unstructured":"Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12(4):492\u2013503.","journal-title":"AAPS J"},{"issue":"2","key":"587_CR73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129\u201338.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"587_CR74","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/oli.2008.0164","volume":"18","author":"MA Behlke","year":"2008","unstructured":"Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides. 2008;18(4):305\u201319.","journal-title":"Oligonucleotides"},{"key":"587_CR75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.addr.2015.10.015","volume":"104","author":"SH Ku","year":"2016","unstructured":"Ku SH, Jo SD, Lee YK, Kim K, Kim SH. Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev. 2016;104:16\u201328.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"587_CR76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd3010","volume":"9","author":"AL Jackson","year":"2010","unstructured":"Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9(1):57\u201367.","journal-title":"Nat Rev Drug Discov"},{"key":"587_CR77","doi-asserted-by":"crossref","unstructured":"Dar SA, et al. siRNAmod: a database of experimentally validated chemically modified siRNAs. Sci Rep. 2016:6.","DOI":"10.1038\/srep20031"},{"issue":"9","key":"587_CR78","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1261\/rna.5103703","volume":"9","author":"YL Chiu","year":"2003","unstructured":"Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA. 2003;9(9):1034\u201348.","journal-title":"RNA"},{"issue":"3","key":"587_CR79","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bbrc.2006.02.049","volume":"342","author":"S Choung","year":"2006","unstructured":"Choung S, Kim YJ, Kim S, Park HO, Choi YC. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun. 2006;342(3):919\u201327.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"587_CR80","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.4049\/jimmunol.180.5.3229","volume":"180","author":"F Eberle","year":"2008","unstructured":"Eberle F, et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol. 2008;180(5):3229\u201337.","journal-title":"J Immunol"},{"issue":"3","key":"587_CR81","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","volume":"13","author":"AD Judge","year":"2006","unstructured":"Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006;13(3):494\u2013505.","journal-title":"Mol Ther"},{"issue":"3","key":"587_CR82","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm1191","volume":"11","author":"V Hornung","year":"2005","unstructured":"Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11(3):263\u201370.","journal-title":"Nat Med"},{"issue":"7014","key":"587_CR83","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nature03121","volume":"432","author":"J Soutschek","year":"2004","unstructured":"Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173\u20138.","journal-title":"Nature"},{"issue":"19","key":"587_CR84","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1016\/j.bmcl.2004.07.018","volume":"14","author":"C Lorenz","year":"2004","unstructured":"Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett. 2004;14(19):4975\u20137.","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"587_CR85","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/nbt1339","volume":"25","author":"C Wolfrum","year":"2007","unstructured":"Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25(10):1149\u201357.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"587_CR86","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203\u201322.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"587_CR87","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","volume":"139","author":"CL Gallant-Behm","year":"2019","unstructured":"Gallant-Behm CL, Piper J, Lynch JM, Seto AG, Hong SJ, Mustoe TA, et al. A microRNA-29 mimic (remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Investig Dermatol. 2019;139(5):1073\u201381.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"587_CR88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/bc800278e","volume":"20","author":"JH Jeong","year":"2009","unstructured":"Jeong JH, Mok H, Oh YK, Park TG. siRNA conjugate delivery systems. Bioconjug Chem. 2009;20(1):5\u201314.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"587_CR89","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967\u201377.","journal-title":"Nat Mater"},{"issue":"7","key":"587_CR90","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A, Querbes W, de S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357\u201364.","journal-title":"Mol Ther"},{"key":"587_CR91","doi-asserted-by":"crossref","unstructured":"Garber K. Alnylam terminates revusiran program, stock plunges. Nat Publ Group. 2016.","DOI":"10.1038\/nbt1216-1213"},{"key":"587_CR92","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cis.2006.05.026","volume":"123-126","author":"P Sharma","year":"2006","unstructured":"Sharma P, Brown S, Walter G, Santra S, Moudgil B. Nanoparticles for bioimaging. Adv Colloid Interf Sci. 2006;123-126:471\u201385.","journal-title":"Adv Colloid Interf Sci"},{"issue":"14","key":"587_CR93","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1039\/C4CS00392F","volume":"44","author":"OS Wolfbeis","year":"2015","unstructured":"Wolfbeis OS. An overview of nanoparticles commonly used in fluorescent bioimaging. Chem Soc Rev. 2015;44(14):4743\u201368.","journal-title":"Chem Soc Rev"},{"issue":"5","key":"587_CR94","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1021\/acs.chemrev.5b00148","volume":"116","author":"GY Chen","year":"2016","unstructured":"Chen GY, et al. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem Rev. 2016;116(5):2826\u201385.","journal-title":"Chem Rev"},{"issue":"10","key":"587_CR95","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1517\/17425247.2010.513969","volume":"7","author":"L Zhu","year":"2010","unstructured":"Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv. 2010;7(10):1209\u201326.","journal-title":"Expert Opin Drug Deliv"},{"key":"587_CR96","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1146\/annurev-bioeng-071813-105119","volume":"16","author":"JM Williford","year":"2014","unstructured":"Williford JM, Wu J, Ren Y, Archang MM, Leong KW, Mao HQ. Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng. 2014;16:347\u201370.","journal-title":"Annu Rev Biomed Eng"},{"issue":"4","key":"587_CR97","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1166\/jbn.2011.1313","volume":"7","author":"S Nimesh","year":"2011","unstructured":"Nimesh S, Gupta N, Chandra R. Cationic polymer based nanocarriers for delivery of therapeutic nucleic acids. J Biomed Nanotechnol. 2011;7(4):504\u201320.","journal-title":"J Biomed Nanotechnol"},{"issue":"12","key":"587_CR98","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1039\/c4nr00018h","volume":"6","author":"D Ma","year":"2014","unstructured":"Ma D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale. 2014;6(12):6415\u201325.","journal-title":"Nanoscale"},{"issue":"8","key":"587_CR99","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2174\/1389201017666160401145319","volume":"17","author":"C Sarisozen","year":"2016","unstructured":"Sarisozen C, Salzano G, Torchilin VP. Lipid-based siRNA delivery systems: challenges, promises and solutions along the long journey. Curr Pharm Biotechnol. 2016;17(8):728\u201340.","journal-title":"Curr Pharm Biotechnol"},{"key":"587_CR100","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jconrel.2016.11.017","volume":"245","author":"A Mokhtarzadeh","year":"2017","unstructured":"Mokhtarzadeh A, Alibakhshi A, Hashemi M, Hejazi M, Hosseini V, de la Guardia M, et al. Biodegradable nano-polymers as delivery vehicles for therapeutic small non-coding ribonucleic acids. J Control Release. 2017;245:116\u201326.","journal-title":"J Control Release"},{"issue":"3","key":"587_CR101","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ppsc.201200061","volume":"30","author":"XQ Liu","year":"2013","unstructured":"Liu XQ, et al. Polymeric-micelle-based nanomedicine for siRNA delivery. Part Part Syst Charact. 2013;30(3):211\u201328.","journal-title":"Part Part Syst Charact"},{"issue":"4","key":"587_CR102","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.nantod.2015.06.008","volume":"10","author":"J Conde","year":"2015","unstructured":"Conde J, et al. 15 years on siRNA delivery: beyond the state-of-the-art on inorganic nanoparticles for RNAi therapeutics. Nano Today. 2015;10(4):421\u201350.","journal-title":"Nano Today"},{"issue":"4","key":"587_CR103","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1517\/17425247.2016.1134486","volume":"13","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Huo S, Hardie J, Liang XJ, Rotello VM. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin Drug Deliv. 2016;13(4):547\u201359.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"587_CR104","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrd1632","volume":"4","author":"VP Torchilin","year":"2005","unstructured":"Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"587_CR105","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.2147\/IJN.S106625","volume":"11","author":"TS Zatsepin","year":"2016","unstructured":"Zatsepin TS, Kotelevtsev YV, Koteliansky V. Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside. Int J Nanomedicine. 2016;11:3077\u201386.","journal-title":"Int J Nanomedicine"},{"issue":"12","key":"587_CR106","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd4685","volume":"14","author":"JE Zuckerman","year":"2015","unstructured":"Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov. 2015;14(12):843\u201356.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"587_CR107","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"587_CR108","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nbt.2614","volume":"31","author":"G Sahay","year":"2013","unstructured":"Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013;31(7):653\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"587_CR109","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.addr.2009.08.004","volume":"62","author":"S Mao","year":"2010","unstructured":"Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62(1):12\u201327.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"587_CR110","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jconrel.2013.08.005","volume":"172","author":"H Ragelle","year":"2013","unstructured":"Ragelle H, Vandermeulen G, Preat V. Chitosan-based siRNA delivery systems. J Control Release. 2013;172(1):207\u201318.","journal-title":"J Control Release"},{"key":"587_CR111","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/B978-0-12-800148-6.00009-2","volume":"88","author":"P Neuberg","year":"2014","unstructured":"Neuberg P, Kichler A. Recent developments in nucleic acid delivery with polyethylenimines. Adv Genet. 2014;88:263\u201388.","journal-title":"Adv Genet"},{"issue":"21","key":"587_CR112","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1016\/j.biomaterials.2011.03.035","volume":"32","author":"OM Merkel","year":"2011","unstructured":"Merkel OM, Urbanics R, Bedocs P, Rozsnyay Z, Rosivall L, Toth M, et al. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Biomaterials. 2011;32(21):4936\u201342.","journal-title":"Biomaterials"},{"issue":"1","key":"587_CR113","first-page":"23","volume":"1","author":"V Kafil","year":"2011","unstructured":"Kafil V, Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cells. Bioimpacts. 2011;1(1):23\u201330.","journal-title":"Bioimpacts"},{"issue":"5","key":"587_CR114","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0142-9612(00)00203-9","volume":"22","author":"WT Godbey","year":"2001","unstructured":"Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials. 2001;22(5):471\u201380.","journal-title":"Biomaterials"},{"issue":"2","key":"587_CR115","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2217\/nnm.13.204","volume":"9","author":"HY Xue","year":"2014","unstructured":"Xue HY, Liu S, Wong HL. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomed (Lond). 2014;9(2):295\u2013312.","journal-title":"Nanomed (Lond)"},{"issue":"27","key":"587_CR116","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1016\/j.biomaterials.2012.05.055","volume":"33","author":"M Zheng","year":"2012","unstructured":"Zheng M, Librizzi D, K\u0131l\u0131\u00e7 A, Liu Y, Renz H, Merkel OM, et al. Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers. Biomaterials. 2012;33(27):6551\u20138.","journal-title":"Biomaterials"},{"issue":"13","key":"587_CR117","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1039\/c2cs35146c","volume":"41","author":"M Jager","year":"2012","unstructured":"Jager M, et al. Branched and linear poly(ethylene imine)-based conjugates: synthetic modification, characterization, and application. Chem Soc Rev. 2012;41(13):4755\u201367.","journal-title":"Chem Soc Rev"},{"issue":"5","key":"587_CR118","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/wnan.1228","volume":"5","author":"S Hobel","year":"2013","unstructured":"Hobel S, Aigner A. Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(5):484\u2013501.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"4","key":"587_CR119","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1021\/nn500704t","volume":"8","author":"KL Kozielski","year":"2014","unstructured":"Kozielski KL, Tzeng SY, de Mendoza BA, Green JJ. Bioreducible cationic polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain cancer cells. ACS Nano. 2014;8(4):3232\u201341.","journal-title":"ACS Nano"},{"issue":"2","key":"587_CR120","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1021\/mp5007213","volume":"12","author":"G Navarro","year":"2015","unstructured":"Navarro G, Pan J, Torchilin VP. Micelle-like nanoparticles as carriers for DNA and siRNA. Mol Pharm. 2015;12(2):301\u201313.","journal-title":"Mol Pharm"},{"issue":"3","key":"587_CR121","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jconrel.2008.10.004","volume":"133","author":"AJ Convertine","year":"2009","unstructured":"Convertine AJ, Benoit DS, Duvall CL, Hoffman AS, Stayton PS. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release. 2009;133(3):221\u20139.","journal-title":"J Control Release"},{"issue":"6","key":"587_CR122","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/mp100253e","volume":"7","author":"WW Gao","year":"2010","unstructured":"Gao WW, Chan JM, Farokhzad OC. pH-responsive nanoparticles for drug delivery. Mol Pharm. 2010;7(6):1913\u201320.","journal-title":"Mol Pharm"},{"key":"587_CR123","doi-asserted-by":"crossref","unstructured":"Baljon J, et al. The efficiency of cytosolic drug delivery using pH-responsive, endosomolytic polymers does not correlate with activation of the NLRP3 inflammasome. Biomater Sci. 2019.","DOI":"10.1039\/C9BM90022E"},{"issue":"2","key":"587_CR124","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.biomaterials.2011.09.061","volume":"33","author":"J Zhou","year":"2012","unstructured":"Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials. 2012;33(2):583\u201391.","journal-title":"Biomaterials"},{"key":"587_CR125","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejps.2016.06.020","volume":"92","author":"MZ Yu","year":"2016","unstructured":"Yu MZ, Pang WH, Yang T, Wang JC, Wei L, Qiu C, et al. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer. Eur J Pharm Sci. 2016;92:39\u201348.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"587_CR126","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/mt.2014.30","volume":"22","author":"Y Ding","year":"2014","unstructured":"Ding Y, Jiang Z, Saha K, Kim CS, Kim ST, Landis RF, et al. Gold nanoparticles for nucleic acid delivery. Mol Ther. 2014;22(6):1075\u201383.","journal-title":"Mol Ther"},{"issue":"14","key":"587_CR127","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2217\/nnm-2018-0520","volume":"14","author":"E Ghaffari","year":"2019","unstructured":"Ghaffari E, et al. Delivery of antisense peptide nucleic acid by gold nanoparticles for the inhibition of virus replication. Nanomed (Lond). 2019;14(14):1827\u201340.","journal-title":"Nanomed (Lond)"},{"issue":"10","key":"587_CR128","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1021\/ar200090c","volume":"44","author":"D Ho","year":"2011","unstructured":"Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res. 2011;44(10):875\u201382.","journal-title":"Acc Chem Res"},{"key":"587_CR129","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/anie.200703039","volume":"47","author":"V Sokolova","year":"2008","unstructured":"Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem (Int Ed Engl). 2008;47:1382\u201395.","journal-title":"Angew Chem (Int Ed Engl)"},{"issue":"1","key":"587_CR130","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1021\/cr300213b","volume":"115","author":"EK Lim","year":"2015","unstructured":"Lim EK, Kim T, Paik S, Haam S, Huh YM, Lee K. Nanomaterials for theranostics: recent advances and future challenges. Chem Rev. 2015;115(1):327\u201394.","journal-title":"Chem Rev"},{"issue":"23","key":"587_CR131","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.1039\/c2nr31775c","volume":"4","author":"A El-Fiqi","year":"2012","unstructured":"El-Fiqi A, et al. Capacity of mesoporous bioactive glass nanoparticles to deliver therapeutic molecules. Nanoscale. 2012;4(23):7475\u201388.","journal-title":"Nanoscale"},{"issue":"5","key":"587_CR132","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.","journal-title":"Nat Rev Mater"},{"key":"587_CR133","doi-asserted-by":"crossref","unstructured":"Garc\u00eda KP, et al. Zwitterionic-coated \u201cstealth\u201d nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. 2014;10(13): 2516\u20132529.","DOI":"10.1002\/smll.201303540"},{"key":"587_CR134","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"Y-N Zhang","year":"2016","unstructured":"Zhang Y-N, Poon W, Tavares AJ, McGilvray I, Chan WCW. Nanoparticle\u2013liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332\u201348.","journal-title":"J Control Release"},{"issue":"3\u20134","key":"587_CR135","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0927-7765(99)00156-3","volume":"18","author":"R Gref","year":"2000","unstructured":"Gref R, L\u00fcck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al. \u2018Stealth\u2019corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B: Biointerfaces. 2000;18(3\u20134):301\u201313.","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"Pt A","key":"587_CR136","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ijbiomac.2016.10.024","volume":"94","author":"R Parveen","year":"2017","unstructured":"Parveen R, Shamsi TN, Fatima S. Nanoparticles-protein interaction: role in protein aggregation and clinical implications. Int J Biol Macromol. 2017;94(Pt A):386\u201395.","journal-title":"Int J Biol Macromol"},{"key":"587_CR137","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.taap.2016.01.005","volume":"299","author":"AN Ilinskaya","year":"2016","unstructured":"Ilinskaya AN, Dobrovolskaia MA. Understanding the immunogenicity and antigenicity of nanomaterials: past, present and future. Toxicol Appl Pharmacol. 2016;299:70\u20137.","journal-title":"Toxicol Appl Pharmacol"},{"key":"587_CR138","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/196476a0","volume":"196","author":"L Vroman","year":"1962","unstructured":"Vroman L. Effect of absorbed proteins on the wettability of hydrophilic and hydrophobic solids. Nature. 1962;196:476\u20137.","journal-title":"Nature"},{"issue":"7","key":"587_CR139","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1073\/pnas.0608582104","volume":"104","author":"T Cedervall","year":"2007","unstructured":"Cedervall T, Lynch I, Lindman S, Bergg\u00e5rd T, Thulin E, Nilsson H, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A. 2007;104(7):2050\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"587_CR140","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1039\/C4CC07644C","volume":"51","author":"J Lazarovits","year":"2015","unstructured":"Lazarovits J, Chen YY, Sykes EA, Chan WC. Nanoparticle-blood interactions: the implications on solid tumour targeting. Chem Commun. 2015;51(14):2756\u201367.","journal-title":"Chem Commun"},{"issue":"17","key":"587_CR141","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1039\/C5CS00217F","volume":"44","author":"D Docter","year":"2015","unstructured":"Docter D, et al. The nanoparticle biomolecule corona: lessons learned - challenge accepted? Chem Soc Rev. 2015;44(17):6094\u2013121.","journal-title":"Chem Soc Rev"},{"issue":"11\u201312","key":"587_CR142","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10337-014-2677-x","volume":"77","author":"AL Capriotti","year":"2014","unstructured":"Capriotti AL, et al. Analytical methods for characterizing the nanoparticle-protein Corona. Chromatographia. 2014;77(11\u201312):755\u201369.","journal-title":"Chromatographia"},{"issue":"10","key":"587_CR143","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nnano.2013.181","volume":"8","author":"S Tenzer","year":"2013","unstructured":"Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772\u201381.","journal-title":"Nat Nanotechnol"},{"issue":"38","key":"587_CR144","doi-asserted-by":"publisher","first-page":"14265","DOI":"10.1073\/pnas.0805135105","volume":"105","author":"M Lundqvist","year":"2008","unstructured":"Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A. 2008;105(38):14265\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"587_CR145","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/(SICI)1097-4636(199711)37:2<229::AID-JBM12>3.0.CO;2-9","volume":"37","author":"E Allemann","year":"1997","unstructured":"Allemann E, et al. Kinetics of blood component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of complement C3 component involvement. J Biomed Mater Res. 1997;37(2):229\u201334.","journal-title":"J Biomed Mater Res"},{"issue":"3","key":"587_CR146","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1023\/A:1018965121222","volume":"11","author":"H Harashima","year":"1994","unstructured":"Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic-uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res. 1994;11(3):402\u20136.","journal-title":"Pharm Res"},{"issue":"1","key":"587_CR147","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","volume":"307","author":"DE Owens 3rd","year":"2006","unstructured":"Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93\u2013102.","journal-title":"Int J Pharm"},{"issue":"12","key":"587_CR148","doi-asserted-by":"publisher","first-page":"10960","DOI":"10.1021\/nn404481f","volume":"7","author":"Y Yan","year":"2013","unstructured":"Yan Y, et al. Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano. 2013;7(12):10960\u201370.","journal-title":"ACS Nano"},{"key":"587_CR149","first-page":"97","volume":"10","author":"YK Lee","year":"2015","unstructured":"Lee YK, et al. Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int J Nanomedicine. 2015;10:97\u2013112.","journal-title":"Int J Nanomedicine"},{"issue":"17","key":"587_CR150","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1039\/C4CS00487F","volume":"44","author":"TL Moore","year":"2015","unstructured":"Moore TL, Rodriguez-Lorenzo L, Hirsch V, Balog S, Urban D, Jud C, et al. Nanoparticle colloidal stability in cell culture media and impact on cellular interactions. Chem Soc Rev. 2015;44(17):6287\u2013305.","journal-title":"Chem Soc Rev"},{"issue":"25","key":"587_CR151","doi-asserted-by":"publisher","first-page":"9673","DOI":"10.1021\/la301104a","volume":"28","author":"JS Gebauer","year":"2012","unstructured":"Gebauer JS, Malissek M, Simon S, Knauer SK, Maskos M, Stauber RH, et al. Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir. 2012;28(25):9673\u20139.","journal-title":"Langmuir"},{"issue":"20","key":"587_CR152","doi-asserted-by":"publisher","first-page":"9303","DOI":"10.1021\/la050588t","volume":"21","author":"SH Brewer","year":"2005","unstructured":"Brewer SH, Glomm WR, Johnson MC, Knag MK, Franzen S. Probing BSA binding to citrate-coated gold nanoparticles and surfaces. Langmuir. 2005;21(20):9303\u20137.","journal-title":"Langmuir"},{"issue":"4","key":"587_CR153","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1021\/bm500199h","volume":"15","author":"L Nuhn","year":"2014","unstructured":"Nuhn L, Gietzen S, Mohr K, Fischer K, Toh K, Miyata K, et al. Aggregation behavior of cationic nanohydrogel particles in human blood serum. Biomacromolecules. 2014;15(4):1526\u201333.","journal-title":"Biomacromolecules"},{"issue":"11","key":"587_CR154","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1021\/bm100971q","volume":"11","author":"K Rausch","year":"2010","unstructured":"Rausch K, Reuter A, Fischer K, Schmidt M. Evaluation of nanoparticle aggregation in human blood serum. Biomacromolecules. 2010;11(11):2836\u20139.","journal-title":"Biomacromolecules"},{"issue":"8","key":"587_CR155","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s12274-015-0780-4","volume":"8","author":"R Cukalevski","year":"2015","unstructured":"Cukalevski R, et al. IgG and fibrinogen driven nanoparticle aggregation. Nano Res. 2015;8(8):2733\u201343.","journal-title":"Nano Res"},{"issue":"7","key":"587_CR156","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1021\/nn2007496","volume":"5","author":"A Albanese","year":"2011","unstructured":"Albanese A, Chan WC. Effect of gold nanoparticle aggregation on cell uptake and toxicity. ACS Nano. 2011;5(7):5478\u201389.","journal-title":"ACS Nano"},{"issue":"8","key":"587_CR157","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1021\/ar500190q","volume":"47","author":"CC Fleischer","year":"2014","unstructured":"Fleischer CC, Payne CK. Nanoparticle-cell interactions: molecular structure of the protein corona and cellular outcomes. Acc Chem Res. 2014;47(8):2651\u20139.","journal-title":"Acc Chem Res"},{"issue":"1","key":"587_CR158","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1021\/acsnano.7b05528","volume":"12","author":"DW Malcolm","year":"2017","unstructured":"\u2022 Malcolm DW, et al. The effects of biological fluids on colloidal stability and siRNA delivery of a pH-responsive micellar nanoparticle delivery system. ACS Nano. 2017;12(1):187\u201397 This study shows serum-induced NP-siRNA aggregation significantly diminishes efficiency of siRNAdelivery by reducing uptake, pH-responsive membrane lysis activity, and NP-siRNA dissociation.","journal-title":"ACS Nano"},{"issue":"43","key":"587_CR159","doi-asserted-by":"publisher","first-page":"24322","DOI":"10.1021\/acsami.5b08805","volume":"7","author":"GR Dakwar","year":"2015","unstructured":"Dakwar GR, Braeckmans K, Demeester J, Ceelen W, de Smedt SC, Remaut K. Disregarded effect of biological fluids in siRNA delivery: human ascites fluid severely restricts cellular uptake of nanoparticles. ACS Appl Mater Interfaces. 2015;7(43):24322\u20139.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"11","key":"587_CR160","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1248\/bpb.20.1183","volume":"20","author":"J Fujisaki","year":"1997","unstructured":"Fujisaki J, Tokunaga Y, Takahashi T, Kimura S, Shimojo F, Hata T. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. V. Biological disposition and targeting characteristics of osteotropic estradiol. Biol Pharm Bull. 1997;20(11):1183\u20137.","journal-title":"Biol Pharm Bull"},{"issue":"9","key":"587_CR161","doi-asserted-by":"publisher","first-page":"9445","DOI":"10.1021\/acsnano.7b05103","volume":"11","author":"Y Wang","year":"2017","unstructured":"Wang Y, Newman MR, Ackun-Farmmer M, Baranello MP, Sheu TJ, Puzas JE, et al. Fracture-targeted delivery of beta-catenin agonists via peptide-functionalized nanoparticles augments fracture healing. ACS Nano. 2017;11(9):9445\u201358.","journal-title":"ACS Nano"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00587-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-020-00587-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00587-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:13:01Z","timestamp":1722877981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-020-00587-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":161,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1007\/s11914-020-00587-2","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"11 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Danielle Benoit and Clyde Overby report grants from National Science Foundation, National Institutes of Health, and New York State Stem Cell Science during the conduct of the study. Benoit and Maureen Newman have a patent (\u201cCompositions Controlled Localized Delivery of Bone Forming Therapeutic Agents.\u201d #9,949,950.\u00d0\u2019d) licensed to Taithera, and a patent (\u2018Anti-Fouling Semi-Random Zwitterionic Peptides.\u2019 #2-20003) pending.Dr. Newman reports grants from National Science Foundation during the conduct of the study and is an employee of Surrozen. Yuchen Wang is employed at Emergent Biosolutions. Dominic Malcolm is a current employee at Athersys, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}